First Time Loading...

Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA

Watchlist Manager
Kiniksa Pharmaceuticals Ltd Logo
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Watchlist
Price: 20.08 USD 3.61% Market Closed
Updated: May 4, 2024

Income Statement

Earnings Waterfall
Kiniksa Pharmaceuticals Ltd

Revenue
301.8m USD
Cost of Revenue
-37m USD
Gross Profit
264.8m USD
Operating Expenses
-295.4m USD
Operating Income
-30.5m USD
Other Expenses
39.2m USD
Net Income
8.6m USD

Income Statement
Kiniksa Pharmaceuticals Ltd

Rotate your device to view
Income Statement
Currency: USD
Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024
Revenue
Revenue
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
8
N/A
20
+157%
39
+94%
71
+84%
90
+27%
177
+97%
220
+24%
236
+7%
281
+19%
249
-11%
270
+9%
302
+12%
Gross Profit
Cost of Revenue
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(2)
(5)
(9)
(13)
(16)
(20)
(23)
(26)
(28)
(31)
(33)
(37)
Gross Profit
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
5
N/A
15
+178%
29
+102%
57
+95%
74
+29%
157
+112%
197
+26%
211
+7%
252
+20%
218
-14%
237
+9%
265
+12%
Operating Income
Operating Expenses
(65)
(77)
(87)
(97)
(108)
(159)
(177)
(182)
(170)
(132)
(124)
(137)
(157)
(177)
(191)
(188)
(186)
(188)
(184)
(189)
(188)
(189)
(214)
(237)
(262)
(295)
Selling, General & Administrative
(9)
(11)
(13)
(16)
(22)
(26)
(30)
(33)
(35)
(35)
(36)
(40)
(45)
(57)
(70)
(79)
(86)
(88)
(90)
(93)
(98)
(105)
(110)
(120)
(129)
(139)
Research & Development
(56)
(66)
(74)
(80)
(87)
(133)
(147)
(148)
(135)
(97)
(88)
(98)
(112)
(120)
(121)
(109)
(99)
(91)
(81)
(79)
(66)
(60)
(70)
(70)
(76)
(87)
Other Operating Expenses
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(1)
(9)
(13)
(17)
(24)
(24)
(34)
(47)
(57)
(69)
Operating Income
(65)
N/A
(77)
-17%
(87)
-13%
(97)
-11%
(108)
-12%
(159)
-47%
(177)
-11%
(182)
-2%
(170)
+6%
(132)
+23%
(124)
+6%
(137)
-10%
(157)
-15%
(177)
-13%
(186)
-5%
(173)
+7%
(157)
+10%
(131)
+17%
(109)
+16%
(32)
+70%
10
N/A
22
+123%
38
+74%
(19)
N/A
(25)
-31%
(31)
-21%
Pre-Tax Income
Interest Income Expense
1
1
2
3
5
6
7
7
6
5
4
2
1
0
0
0
0
0
0
1
1
3
5
7
9
9
Pre-Tax Income
(65)
N/A
(76)
-17%
(85)
-12%
(94)
-10%
(103)
-10%
(153)
-48%
(170)
-11%
(175)
-3%
(164)
+6%
(127)
+23%
(121)
+5%
(135)
-12%
(156)
-16%
(177)
-13%
(186)
-5%
(173)
+7%
(157)
+10%
(131)
+17%
(109)
+16%
(32)
+71%
11
N/A
25
+127%
43
+72%
(12)
N/A
(17)
-36%
(22)
-30%
Net Income
Tax Provision
0
0
0
0
0
0
0
2
2
4
(2)
(5)
(5)
(8)
(3)
(2)
(1)
(3)
(3)
174
172
171
188
6
31
30
Income from Continuing Operations
(65)
(76)
(85)
(93)
(103)
(153)
(170)
(173)
(162)
(122)
(123)
(140)
(161)
(184)
(189)
(175)
(158)
(134)
(112)
143
183
196
231
(7)
14
9
Net Income (Common)
(65)
N/A
(76)
-17%
(85)
-12%
(93)
-10%
(103)
-11%
(153)
-48%
(170)
-11%
(173)
-2%
(162)
+6%
(122)
+24%
(123)
0%
(140)
-14%
(161)
-16%
(184)
-14%
(189)
-2%
(175)
+7%
(158)
+10%
(134)
+15%
(112)
+16%
143
N/A
183
+29%
196
+7%
231
+18%
(7)
N/A
14
N/A
9
-39%
EPS (Diluted)
-1.34
N/A
-1.55
-16%
-1.73
-12%
-1.9
-10%
-2.09
-10%
-2.95
-41%
-3.12
-6%
-3.14
-1%
-2.99
+5%
-2.23
+25%
-2.11
+5%
-2.11
N/A
-2.61
-24%
-2.7
-3%
-2.75
-2%
-2.56
+7%
-2.3
+10%
-1.94
+16%
-1.62
+16%
2.02
N/A
2.6
+29%
2.81
+8%
3.22
+15%
-0.11
N/A
0.2
N/A
0.12
-40%

See Also

Discover More